Double ?-lactam regimen compared to an aminoglycoside/?-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients
| Autor: | Bary W. Brown, Kathryn A. Newman, Jai H. Joshi, Mark Moody, Rebecca S. Finley, Robert L. Ruxer, Stephen C. Schimpff |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent Fever Secondary infection Ceftazidime Bacteremia Microbial Sensitivity Tests Gastroenterology Nephrotoxicity Leukocyte Count Neoplasms Internal medicine medicine Tobramycin Humans Serum Bactericidal Test Prospective Studies Aged Piperacillin business.industry Incidence Aminoglycoside Drug Synergism Middle Aged medicine.disease Regimen Logistic Models Oncology Superinfection Immunology Drug Therapy Combination Drug Monitoring business Agranulocytosis Granulocytes medicine.drug |
| Zdroj: | Supportive Care in Cancer. 1:186-194 |
| ISSN: | 1433-7339 0941-4355 |
| Popis: | In a prospective, randomized trial, 205 febrile episodes in granulocytopenic cancer patients were treated with ceftazidime with or without tobramycin (C±T), both agents being administered only if the initial granulocyte count was below 200/μl, or ceftazidime plus piperacillin (C+P). The overall response rate was 71% (39 of 60 for C±T and 45 of 58 for C+P). Logistic regression analyses documented no evidence of a significant difference between the two regimens in overall treatment effect after accounting for the linear effects of potentially important variables, such as infection type and granulocyte count. Although the response rates for the subgroup of patients with bacteremias was better with the C+P regimen (P=0.06), there was no difference in response for patients with bacteremia and profound ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink